Emerging tocolytics for maintenance therapy of preterm labour: Oxytocin antagonists and calcium channel blockers

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 113, Issue SUPPL. 3, 2006, Pages 113-115

  Kim, A ^a   Shim, J Y ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Atosiban; Maintenance tocolysis; Nifedipine; Preterm birth; Preterm labour

Indexed keywords

ATOSIBAN; BARUSIBAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; MAGNESIUM SULFATE; NIFEDIPINE; OXYTOCIN ANTAGONIST; PLACEBO; RITODRINE; UTERUS SPASMOLYTIC AGENT; VERAPAMIL;

CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; MEDICAL SOCIETY; NAUSEA AND VOMITING; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; NIFEDIPINE; OBSTETRIC LABOR, PREMATURE; OXYTOCIN; PREGNANCY; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 33845589224     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01135.x     Document Type: Review

References (22)

1. Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al. Tocolytic treatment for the management of preterm labour: a review of the evidence. Am J Obstet Gynecol 2003;188:1648-59.
2. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94:869-77.
3. Tocolytic Drugs for Women in Preterm Labour. Clinical Guideline No. 1(B). Royal College of Obstetricians and Gynaecologists, 2002. [www.rcog.org.uk/ resources/Public/pdf/Tocolytic_Drugs_No1(B).pdf]. Accessed 19 October 2006.
4. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191-9.
5. The Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. BJOG 2001;108:133-42.
6. Norwitz ER, Bahtiyar MO, Sibai BM. Defining standards of care in maternal-fetal medicine. Am J Obstet Gynecol 2004;191:1491-6.
7. Cook CM, Peek MJ. Survey of the management of preterm labour in Australia and New Zealand in 2002. Aust N Z J Obstet Gynaecol 2004;44:35-8.
8. Thornton JG. Maintenance tocolysis. BJO G 2005;112(Suppl 1):118-21.
9. Kinsler VA, Thornton S, Ashford ML, Melin P, Smith SK. The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Br J Obstet Gynaecol 1996;103:373-5.
10. Engstrom T, Bratholm P, Vilhardt H, Christensen NJ. Effect of oxytocin receptor and beta2-adrenoceptor blockade on myometrial oxytocin receptors in parturient rats. Biol Reprod 1999;60:322-9.
11. Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol 1995;173:913-7.
12. Valenzuela GJ, Sanchez-Ramos L, Romero R, Silver HM, Koltun WD, Millar L, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000;182:1184-90.
13. Goodwin TM, Valenzuela GJ, Silver H, Creasy G. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group. Obstet Gynecol 1996;88:331-6.
14. Reinheimer TM, Bee WH, Resendez JC, Meyer JK, Haluska GJ, Chellman GJ. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 2005;90:2275-81.
15. Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, et al. Pharmacology of (2S, 4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4- (methoxyimino)-1-[(2#-methyl[1, 1#-biphenyl]-4-yl)carbonyl]-2- pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther 2003;306:253-61.
16. Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, et al. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3- methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther 2004;309:414-24.
17. King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol 2003;43:192-8.
18. Carr DB, Clark AL, Kernek K, Spinnato JA. Maintenance oral nifedipine for preterm labor: a randomized clinical trial. Am J Obstet Gynecol 1999;181:822-7.
19. Sayin NC, Varol FG, Balkanli-Kaplan P, Sayin M. Oral nifedipine maintenance therapy after acute intravenous tocolysis in preterm labor. J Perinat Med 2004;32:220-4.
20. Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, van Geijn HP, Bleker OP, et al. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006;113:324-31.
21. Ferguson JE II, Schutz T, Pershe R, Stevenson DK, Blaschke T. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol 1989;161:1485-90.
22. Lamont RF. Reply to article by King et al. Aust N Z J Obstet Gynaecol 2004;44:275-6.